Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The SURPASS phase 3 clinical trial programme explored the efficacy and safety of tirzepatide in people with type 2 diabetes, and demonstrated dose-dependent reductions in HbA 1c of 2028 mmol/mol in those treated with tirzepatide: greater reductions than those achieved with semaglutide (Fras et al, 2021), insulin degludec (Ludvik et al, 2021) and insulin glargine (Del Prato et al, 2021), with reductions sustained up to 2 years in SURPASS-4
This is not an accident
( D ) Plasma DPP4 protein
Non-Recourse Debt Most DST-related debt is non-recourse
US$ 24.32
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 20.30
US$ 23.37
US$ 28.27
US$ 22.81
